LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024

September 09, 2024 | Last Trade: US$2.25 0.02 -0.88
  • Meet with Modular Medical CEO, Jeb Besser

  • There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.

  • Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association

  • About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks

SAN DIEGO, CA / ACCESSWIRE / September 9, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity." The event is scheduled to begin at 8:30am pacific/11:30am eastern on Wednesday, September 11, 2024. To register to join the complimentary event, please visit the Tribe Public LLC at MODD-GLP-1.TribePublic.com.

HealthStocksHub

Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at This email address is being protected from spambots. You need JavaScript enabled to view it.or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

About Modular Medical

Modular Medical, Inc. (Nasdaq: MODD) is a medical device company that will launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and clinical efficacy, thereby making top quality insulin delivery both affordable and simple to learn. The Company's mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing diabetes care for the rest of us.

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

ABOUT TRIBE PUBLIC LLC

Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website to learn more: http://www.tribepublic.com/

CONTACT:

Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB